FDA
-
-
-
-
-
-
-
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
-
-
-
-
-
-
-
Lexaria extends pharmaceutical partnership through december 2026
-
-
-
-
-
-
-
Lexaria signs contracts for human study of oral semaglutide formulation
-
-
-
-
-
-
-
Lexaria Announces New R&D Plans for 2026
-
-
-
-
-
-
-
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
-
-
-
-
-
-
-
Lexaria extends pharmaceutical partnership agreement through April 2026
-
-
-
-
-
-
-
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
326,551 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

